All News
IL-23 Blockade Goes Oral
A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
Read Article
IL-23 Blockade Goes Oral
A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and https://t.co/7awBk16ZrQ
Dr. John Cush RheumNow ( View Tweet)
Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO
@Janetbirdope pearls in rheumatology.
Sero negative inflammatory arthritis ? Or is it? Look at the toes for early signs of PsA.
In my clinic ITS inflammatory arthritis to determine etiology .
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Can we catch PsA before it starts?
My take on #ABSTRACT0877 for #ACR25
@RheumNow
https://t.co/Rw2gJ4XSsz
Aurelie Najm AurelieRheumo ( View Tweet)
Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO
Mos. 4-6: >10% improvement in alopecia w/Cenerimod
Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod
Early improvement in alopecia & ulcers w/Cenerimod
Promising?
#ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr
sheila RHEUMarampa ( View Tweet)
Cutaneous vasculitis: who is most likely to have systemic disease?
430 pt w skin vasculitis examined in case-control
Associated with risk for systemic vasculitis/CTD:
- GI sx
- ulcerating/necrotic lesions
- constitutional sx
- hematuria
@RheumNow #ACR25 Abst 2525 https://t.co/lRjLKRYxDW
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
#1725 Functional NOTCH4 variants contribute to vasculopathy & fibrosis in SSc, particularly in African-American patients
NOTCH4 hyperactivation disrupts angiogenesis & drives EndoMT; inhibition (including with FDA-approved Nirogacestat) restores vascular repair @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumomab in #SLE @RheumNow
https://t.co/5JrLG41nsD https://t.co/KeY6AkHUNK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Stress Raises the Risk of Psoriasis
New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation experienced during the first year of life may triple the risk of developing psoriasis later in life. https://t.co/TSXoQKjRPN
Dr. John Cush RheumNow ( View Tweet)
X-sectional study by Dr Toledano et al showed that 20% (46/230) PsA pts had restless leg syndrome (RDS).
Pts w/ RDS:
- Polyarthritis
⬆️ Swollen jts
⬆️ Fatigue, anxiety, depression
⬆️ Dse activity
Poor sleep quality
Polyarthritis & Pso: assocd w/ RDS
#ACR25 @RheumNow Abs1413 https://t.co/8Ds3TgLjs1
sheila RHEUMarampa ( View Tweet)
In ICONIC-LEAD, adolescents (12 to <18 years) with moderate-to-severe psoriasis treated with icotrokinra (ICO) achieved Investigator Global Assessment (IGA) 0/1 in 84.1% vs 27.3% (placebo) and PASI 90 in 70.5% vs 13.6% at Week 16. Week 24 responses reached 88.6%. Safety profile https://t.co/L7h8BlnWaO
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Icotrokinra, the new kid on the bloc!
Targeted oral peptide IL-23R-inhibitor
Effective in Ph2 and Ph3 in PSO Adults
Data in Adolescents (12-18yo) with PSO
ICO 200mg QD 44pts vs. PBO 22pts 16wks
All pts received ICO wk16-wk24
Clear/Almost clear skin IGA 0/1 84% vs. 24%
PASI 90 https://t.co/77YvXtdLi1
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
A closer look in skin toxicity of GCs in RMDs
GC Toxicity Index, LONG TOX prospective cohort
Frequent:
-Easy bruising 35%
-Atrophy 22%
-Hirsutism 17%
-Acneiform rash 15%
-Erosion/Tear 12%
GC-related Neuropsychiatric toxicity highly associated with/ skin, something to look out https://t.co/NfxG8JkxSP
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#802 In #SLE pts with CLASI-A ≥8, pooled post-hoc analysis of Phase 2 RCT showed enpatoran, oral small molecule toll-like receptor 7/8-i impoved cutaneous response vs PBO as early as WK4. First-in-class promising therapy & warrant investigation in Phase 3 @RheumNow https://t.co/rn6NXdiGjD
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts
IL-23i and IL-17Ai associated w/
-lower risks of diabetes
-Diabetic nephropathy
-Stage 3–5 CKD
and reduced risk compared to TNFi treated and bionaive pts
Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Redefining When to Biopsy the Kidney in Patients with SLE # Petri et al. ACR 2025 - Lupus nephritis may be seen in lower proteinuria too (69%)
Happy to share similar results from our study-Padiyar S, As C, Gowri M, Mathew J. Lupus. 2024;33(13):1511-1517.
@RheumNow
Dr Shivraj Padiyar DrPadiyar ( View Tweet)
#Cancers esp #hematologic & #lung are ⬆️in Pts w #inflammatory #rheum #diseases
Odds ratios of hem malignancies are wide
& risk stratification is imp
Are we doing a good job?
🤔skin cancer screening ??- not as per general standards
Abst#0172 #ACR25 @RheumNow @ACRheum https://t.co/Uve9knXD3o
Links:
Janet Pope Janetbirdope ( View Tweet)
Icotrokinra, a first-in-class targeted oral peptide IL-23R inhibitor, cleared scalp (66%), genital (77%), and overall skin (57%) PsO vs placebo at Week 16. Basket trial design enabled targeted evaluation. Safety profile favorable. Abstract 0555 @RheumNow #ACR25
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective
@RheumNow #ACR25 https://t.co/TJ4d56oBaJ
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
